Make Better Decisions

  • Identify first generic entrants
  • Uncover prior art in expired and abandoned patents
  • Drug patents in 130+ countries
➤ Start Trial

or, See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Fuji
AstraZeneca
US Department of Justice
Boehringer Ingelheim
Queensland Health
Harvard Business School
UBS
Chinese Patent Office
McKinsey
Merck

Generated: January 17, 2018

DrugPatentWatch Database Preview

PRIMAXIN Drug Profile

« Back to Dashboard

When do Primaxin patents expire, and when can generic versions of Primaxin launch?

Primaxin is a drug marketed by Merck and is included in three NDAs.

The generic ingredient in PRIMAXIN is cilastatin sodium; imipenem. There are sixteen drug master file entries for this compound. Four suppliers are listed for this compound. Additional details are available on the cilastatin sodium; imipenem profile page.

US Patents and Regulatory Information for PRIMAXIN

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Merck PRIMAXIN cilastatin sodium; imipenem INJECTABLE;INJECTION 062756-001 Jan 8, 1987 DISCN No No ➤ Subscribe ➤ Subscribe ➤ Subscribe
Merck PRIMAXIN cilastatin sodium; imipenem POWDER;INTRAMUSCULAR 050630-002 Dec 14, 1990 DISCN No No ➤ Subscribe ➤ Subscribe ➤ Subscribe
Merck PRIMAXIN cilastatin sodium; imipenem INJECTABLE;INJECTION 062756-002 Jan 8, 1987 DISCN No No ➤ Subscribe ➤ Subscribe ➤ Subscribe
Merck PRIMAXIN cilastatin sodium; imipenem POWDER;INTRAMUSCULAR 050630-001 Dec 14, 1990 DISCN No No ➤ Subscribe ➤ Subscribe ➤ Subscribe
Merck PRIMAXIN cilastatin sodium; imipenem POWDER;INTRAVENOUS 050587-002 Nov 26, 1985 AP RX Yes Yes ➤ Subscribe ➤ Subscribe ➤ Subscribe
Merck PRIMAXIN cilastatin sodium; imipenem POWDER;INTRAVENOUS 050587-001 Nov 26, 1985 AP RX Yes Yes ➤ Subscribe ➤ Subscribe ➤ Subscribe
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Expired US Patents for PRIMAXIN

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Merck PRIMAXIN cilastatin sodium; imipenem POWDER;INTRAMUSCULAR 050630-001 Dec 14, 1990 ➤ Subscribe ➤ Subscribe
Merck PRIMAXIN cilastatin sodium; imipenem POWDER;INTRAMUSCULAR 050630-002 Dec 14, 1990 ➤ Subscribe ➤ Subscribe
Merck PRIMAXIN cilastatin sodium; imipenem POWDER;INTRAVENOUS 050587-002 Nov 26, 1985 ➤ Subscribe ➤ Subscribe
Merck PRIMAXIN cilastatin sodium; imipenem POWDER;INTRAVENOUS 050587-001 Nov 26, 1985 ➤ Subscribe ➤ Subscribe
Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

US Department of Justice
Harvard Business School
Accenture
Moodys
AstraZeneca
Chinese Patent Office
Dow
Medtronic
Chubb

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot